Baxter’s Homechoice Claria APD System Receives the US FDA’s 510 (k) Clearance for Kidney Failure
Shots: Boston acquired BTG in all stocks transaction, for ~$1.07/per share at a premium of 36.6%, with total deal value of $4.2B. The transaction is expected to close in H1’19 The acquisition will strengthen Boston’s peripheral intervention platform with BTG’s minimally-invasive treatments like TheraSphere Y-90 radiotherapy, GALI cryoablation and EKOS Endovascular System for treatment of […]Read More
